Profiles

In the seven years that Gillian has worked at Portola, she has focused her efforts on the Company’s pipeline products, including developing assays to more accurately predict the activity of anti-thrombotic agents in Portola’s P2Y₁₂ program. She also has assisted with screening efforts for the Company’s Syk-specific inhibitor program. Her previous experience provided her with the training and background in platelet biology required to develop new technologies to measure platelet function. At Portola, she has played a key role in implementing the Perfusion Chamber Assay in multiple Phase 1 and 2 studies. This allowed the reconstitution of the thrombotic process in vitro, and the monitoring of the modulation of thrombosis by antiplatelet agents. Gillian is motivated by “The rigorous science we do at Portola combined with a focus on improving the care of patients with cardiovascular conditions.”